Also: Oma Fertility emerges from stealth with $37.5 million in equity and debt financing, and payer data platform Abacus Insights scores $28 million.
Medical devicemaker MicroTransponder wrapped up a $53 million Series E funding round led by US Venture Partners.
The raise also included participation from GPG Ventures, Exceller Hunt Ventures, Osage University Partners, Action Potential Venture Capital and the Vertical Group. The company said it will use the capital to commercialize its Vivistim vagus nerve stimulation system, an implantable device that aims to improve hand and arm mobility in stroke patients.
“Our investors are energized by MicroTransponder’s vision to enable treatment for the millions of stroke survivors that have ongoing moderate to severe upper limb impairment. Our goal has always been to establish Vivistim Paired VNS as the gold-standard stroke rehabilitation intervention. Today is the day this therapy can help more stroke survivors get back to the daily activities, hobbies and experiences they love,” CEO and director Richard Foust said in a statement.
Oma Fertility emerged from stealth last week with $37.5 million, including $29 million in equity and another $8.5 million in debt financing.
The seed and Series A rounds were led by JAZZ Venture Partners, Root Ventures, Mithril Capital, Global Asset Capital and Free Solo Ventures. The debt facility came from Silicon Valley Bank. The fertility startup’s first product is aimed at identifying the healthiest sperm to improve IVF outcomes.
“Oma Fertility is capitalizing on the opportunity to bring leading-edge technological advancements to the fertility space, meeting the demands of rising infertility rates,” cofounder and CEO Gurjeet Singh said in a statement. “Our mission is to improve outcomes for more families facing fertility issues and we strive to create a place where everyone seeking to have a child has access to the most advanced, successful fertility treatments.”
RELATED: Artio Medical adds $28M in oversubscribed Series A
Payer-focused healthcare data startup Abacus Insights scooped up $28 million in Series C funding, bringing its total raise to $81 million.
The round was led by MultiPlan Corporation with participation from Blue Venture Fund, CRV, .406 Ventures, Horizon Healthcare Services Inc. and Echo Health Ventures. Abacus raised $35 million in Series B funding in 2020.
It plans to use the investment to grow its business, improve on its platform and hire more staffers.
“This new funding validates our company’s mission, which is to help health plans liberate health data,” CEO and founder Dr. Minal Patel said in a statement. “Doing so empowers consumers to make better health choices and physicians to make more informed treatment decisions. Payors also use the platform to drive efficiency in their business which further lowers costs for their members. We are proud to partner with MultiPlan given their leadership position in data and analytics serving nearly every payor in the country.”
Self-pay healthcare marketplace Sesame raised $27 million in a Series B round led by GV.
Virgin Group, TeleSoft Partners, FMZ Ventures, General Catalyst, Industry Ventures, Coefficient Capital, Giant Ventures and Alumni Ventures Group also participated in the raise. Sesame plans to use the capital to grow the startup and launch its subscription program out of beta.
“Sesame provides greater access to healthcare for a meaningful percentage of the population, and we’re inspired by the company’s mission to drive better patient outcomes for underserved communities,” Cathy Friedman, executive venture partner at GV, said in a statement.
“Sesame presents a compelling opportunity to develop a dynamic marketplace at a scale unlike any in the current U.S. healthcare ecosystem. We’re thrilled to partner with David Goldhill and the entire Sesame team as they move into this next phase of growth.”
